114 related articles for article (PubMed ID: 24560204)
21. The impact of acute urinary retention after iodine-125 prostate brachytherapy on health-related quality of life.
Roeloffzen EM; Hinnen KA; Battermann JJ; Monninkhof EM; van Roermund JG; van Gellekom MP; Frank SJ; van Vulpen M
Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1322-8. PubMed ID: 19939578
[TBL] [Abstract][Full Text] [Related]
22. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
23. Celecoxib to decrease urinary retention associated with prostate brachytherapy.
Feigenberg SJ; Wolk KL; Yang CH; Morris CG; Zlotecki RA
Brachytherapy; 2003; 2(2):103-7. PubMed ID: 15062148
[TBL] [Abstract][Full Text] [Related]
24. Does neoadjuvant hormonal therapy improve urinary function when given to men with large prostates undergoing prostate brachytherapy?
Stone NN; Marshall DT; Stone JJ; Cesaretti JA; Stock RG
J Urol; 2010 Feb; 183(2):634-9. PubMed ID: 20018308
[TBL] [Abstract][Full Text] [Related]
25. Re: Late urinary morbidity with high dose prostate brachytherapy as a boost to conventional external beam radiation therapy for local and locally advanced prostate cancer.
Deger S
J Urol; 2004 Sep; 172(3):1198; author reply 1198. PubMed ID: 15311075
[No Abstract] [Full Text] [Related]
26. Factors predicting for urinary morbidity following 125iodine transperineal prostate brachytherapy.
Williams SG; Millar JL; Duchesne GM; Dally MJ; Royce PL; Snow RM
Radiother Oncol; 2004 Oct; 73(1):33-8. PubMed ID: 15465143
[TBL] [Abstract][Full Text] [Related]
27. Urinary side effects and complications after permanent prostate brachytherapy: the MD Anderson Cancer Center experience.
Anderson JF; Swanson DA; Levy LB; Kuban DA; Lee AK; Kudchadker R; Phan J; Bruno T; Frank SJ
Urology; 2009 Sep; 74(3):601-5. PubMed ID: 19589580
[TBL] [Abstract][Full Text] [Related]
28. Peak flow rate is the best predictor of acute urinary retention following prostate brachytherapy: our experience and literature review.
Ikeda T; Shinohara K
Int J Urol; 2009 Jun; 16(6):558-60. PubMed ID: 19456987
[TBL] [Abstract][Full Text] [Related]
29. Pretreatment nomogram to predict the risk of acute urinary retention after I-125 prostate brachytherapy.
Roeloffzen EM; van Vulpen M; Battermann JJ; van Roermund JG; Saibishkumar EP; Monninkhof EM
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):737-44. PubMed ID: 20888131
[TBL] [Abstract][Full Text] [Related]
30. Prediction of genitourinary tract morbidity after brachytherapy for prostate adenocarcinoma.
Wehle MJ; Lisson SW; Buskirk SJ; Broderick GA; Young PR; Igel TC
Mayo Clin Proc; 2004 Mar; 79(3):314-7. PubMed ID: 15008604
[TBL] [Abstract][Full Text] [Related]
31. Factors associated with the frequency of self-intermittent catheterization after prostate brachytherapy.
Schwartz DJ; Schild SE; Wong WW; Vora SA
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):60-3. PubMed ID: 15629594
[TBL] [Abstract][Full Text] [Related]
32. Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity after permanent interstitial brachytherapy.
Hinerman-Mulroy A; Merrick GS; Butler WM; Wallner KE; Allen Z; Adamovich E
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1367-82. PubMed ID: 15275722
[TBL] [Abstract][Full Text] [Related]
33. Long-term urinary sequelae following 125iodine prostate brachytherapy.
Crook J; Fleshner N; Roberts C; Pond G
J Urol; 2008 Jan; 179(1):141-5; discussion 146. PubMed ID: 17997424
[TBL] [Abstract][Full Text] [Related]
34. Health-related quality of life after single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for prostate cancer.
Morton GC; Loblaw DA; Chung H; Tsang G; Sankreacha R; Deabreu A; Zhang L; Mamedov A; Cheung P; Batchelar D; Danjoux C; Szumacher E
Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1299-305. PubMed ID: 20708853
[TBL] [Abstract][Full Text] [Related]
35. The pathophysiology of lower urinary tract symptoms after brachytherapy for prostate cancer.
Blaivas JG; Weiss JP; Jones M
BJU Int; 2006 Dec; 98(6):1233-7; discussion 1237. PubMed ID: 17125481
[TBL] [Abstract][Full Text] [Related]
36. Cystourethroscopic findings before and after prostate brachytherapy.
Gray G; Wallner K; Roof J; Corman J
Tech Urol; 2000 Jun; 6(2):109-11. PubMed ID: 10798810
[TBL] [Abstract][Full Text] [Related]
37. Previous transurethral resection of the prostate is not a contraindication to high-dose rate brachytherapy for prostate cancer.
Luo HL; Fang FM; Chuang YC; Chiang PH
BJU Int; 2009 Dec; 104(11):1620-3. PubMed ID: 19624535
[TBL] [Abstract][Full Text] [Related]
38. Factors predicting for urinary incontinence after prostate brachytherapy.
McElveen TL; Waterman FM; Kim H; Dicker AP
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1395-404. PubMed ID: 15275725
[TBL] [Abstract][Full Text] [Related]
39. [Transurethral resection of the prostate for urinary retention after seed implantation for prostate cancer: report of 2 cases].
Yang WZ; Guo JY; Li Y; An F; Zhang YQ; Ma T
Zhonghua Nan Ke Xue; 2011 Nov; 17(11):1011-3. PubMed ID: 22141273
[TBL] [Abstract][Full Text] [Related]
40. A Spanner in the works: the use of a new temporary urethral stent to relieve bladder outflow obstruction after prostate brachytherapy.
Henderson A; Laing RW; Langley SE
Brachytherapy; 2002; 1(4):211-8. PubMed ID: 15062169
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
